medigraphic.com
ISSN 1608-8921 (Print)

2022, Number 3

<< Back Next >>

Gaceta Médica Espirituana 2022; 24 (3)

Cancer and COVID-19, a dangerous association

Rodríguez MY, Díaz AMT, Rodríguez DR

Language: Spanish
References: 40
Page: 1-17
PDF size: 364.69 Kb.


ABSTRACT

Background: COVID-19 is a pandemic caused by the SARS-CoV-2 virus which relation with cancer may have adverse effects.
Objective: To describe the main associations between cancer and COVID-19.
Methodology: A literature review was conducted in Google Scholar, SciELO and PubMed Central with the descriptors SARS-CoV-2, COVID-19 and cancer, consulted in DeCS. Full-text articles in Spanish and English were selected, mainly from peer-reviewed journals.
Results: COVID-19 produces more non-favorable outcomes in patients with cancer. These outcomes are related to high hospitalization rates, complications and mortality. Frequent comorbidity relations in patients with cancer seem to contribute to this dangerous association. Signaling pathways common to cancer and SARS-CoV-2 infection are proinflammatory cytokines, type I interferon, androgen receptor, and immune checkpoints. This knowledge has a practical use with drugs against COVID-19 in patients with cancer.
Conclusions: Cancer is associated with severe COVID-19, making such patients more vulnerable to viral infection.


REFERENCES

  1. Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA. Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mech Ageing Dev [Internet]. 2017 [cited 2022 Jan 15];164:113-126. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788911/pdf/nihms887025.pdf 1.

  2. Rubio MC, Sanchez L, Abreu-Ruíz G, Bermejo-Bencomo W, Crombet T, Lage A. COVID-19 and Cancer in Cuba. Seminars in Oncology [Internet]. 2020 [cited 2022 Jan 15];47(5):328-329. Available from: Available from: https://www.sciencedirect.com/science/article/abs/pii/S0093775420300865 2.

  3. Garrido-Tapia E, Manso-López A, Salermo-Reyes M, Ramírez-Ramírez G, Pérez-Rodríguez V. Características clínico-epidemiológicas y algunas reflexiones sobre la COVID-19 en Holguín, Cuba, 2020. CCM [Internet]. 2020 [citado 20 Abr 2022];24(3):839-55. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/correo/ccm-2020/ccm203b.pdf 3.

  4. Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol [Internet]. 2021 [cited 2022 Apr 20];14(1):38. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910769/pdf/13045_2021_Article_1046.pdf 4.

  5. Castañeda CA, Castillo M, Rojas JL, Fuentes H, Gómez HL. COVID-19 en pacientes con cáncer: revisión sistemática. Rev Peru Med Exp Salud Publica [Internet]. 2020 [citado 20 Abr 2022];37(4):611-619. Disponible en: Disponible en: https://scielosp.org/article/rpmesp/2020.v37n4/611-619/es/ 5.

  6. Serra Valdés MÁ. Las enfermedades crónicas no transmisibles y la pandemia por COVID-19. Finlay [Internet]. 2020 [citado 20 Abr 2022];10(2):78-8. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/finlay/fi-2020/fi202c.pdf 6.

  7. Petrova D, Pérez-Gómez B, Pollán M, Sánchez MJ. Implicaciones de la pandemia por COVID-19 sobre el cáncer en España. Med Clin (Barc) [Internet].2020 [citado 20 Abr 2022];155(6):263-266. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205671/pdf/main.pdf 7.

  8. Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Trans R Soc Trop Med Hyg [Internet]. 2022 [cited 2022 Sep 20];0:1-31. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992310/pdf/trac015.pdf 8.

  9. Van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, et al. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev.[Internet] 2020 [cited 2022 Jan 15];89. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351667/pdf/main.pdf 9.

  10. Shumilov E, Hoffknecht P, Koch R, Peceny R, Voigt S, Schmidt N, et al. Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. Cancers [Internet]. 2021 [cited 2022 Jan 15];13. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230714/pdf/cancers-13-02917.pdf 10.

  11. Dovey Z, Mohamed N, Gharib Y, Ratnani P, Hammouda N, Nair SS, et al. Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. Eur Urol Open Sci [Internet]. 2020 [cited 2022 Jan 15];20:1-11. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S2666168320351120 11.

  12. Berzenji L, Vercauteren L, Yogeswaran SK, Lauwers P, Hendriks JM, Van Schil PE. Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance. Cancers [Internet]. 2022 [cited 2022 Sep 15];14:1334. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296308/pdf/main.pdf 12.

  13. Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer [Internet]. 2021 [cited 2022 Jan15];20. Available from: Available from: https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/s12943-021-01363-1.pdf 13.

  14. Ye C, Qi L, Wang J, Zheng S. COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Front Med.[Internet] 2021 [cited 2022 Jan 15];8. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039300/pdf/fmed-08-606755.pdf 14.

  15. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol [Internet] 2021 [cited 2022 Apr 20];18(5):313-319. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957448/pdf/41571_2021_Article_487.pdf 15.

  16. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol [Internet]. 2022 [cited 2022 Apr 20];33(3):340-346. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704021/pdf/main.pdf 16.

  17. Heudel P, Favier B, Solodky ML, Assaad S, Chaumard N, Tredan O, et al. Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients. Eur J Cancer [Internet]. 2022 [cited 2022 Apr 20];17. Available from: Available from: https://reader.elsevier.com/reader/sd/pii/S0959804922000685?token=3DAE247C139184CE04F077F175E7F7D27EC7222D317D1DC99A8CE7DB5FEEAB7522C0F7E4D186F8D9C9D1B99F928518A5&originRegion=eu-west-1&originCreation=20220613163009ç 17.

  18. Pathania AS, Prathipati P, Abdul BAA, Chava S, Katta SS, Gupta SC, et al. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics [Internet]. 2021 [cited 2022 Jan 15];11(2):731-753. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738845/pdf/thnov11p0731.pdf 18.

  19. Díaz-Armas M, Sánchez-Artigas R, Matute-Crespo T, Llumiquinga-Achi R. Proteína de la espícula del virus SARS-CoV-2 y su relación con la enzima convertidora de angiotensina-2. Rev Inf Científ [Internet]. 2021 [citado 14 Abr 2022];100(5). Disponible en: Disponible en: http://www.revinfcientifica.sld.cu/index.php/ric/article/view/3633/4918 19.

  20. Expósito-Lara A, Feria-Díaz G, González-Benítez S, Miguel-Soca P. Variantes genéticas del SARS-CoV-2 y sus implicaciones clínicas. Medisan [Internet]. 2021 [citado 14 Abr 2022];25(6):[aprox.22p.]. Disponible en: Disponible en: http://www.medisan.sld.cu/index.php/san/article/view/3878 20.

  21. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmaco [Internet]. 2021 [2022 Jan 15];90. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709613/pdf/main.pdf 21.

  22. Luo J, Rizvi, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol [Internet]. 2020 [cited 2022 Jan 15];31(10):1386-1396. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/pdf/main.pdf 22.

  23. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol [Internet]. 2020 [cited 2022 Jan 15];31(7):894-901. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270947/pdf/main.pdf 23.

  24. Amador M, Matias-Guiu X, Sancho-Pardo G, Contreras Martinez J, de la Torre-Montero JC, Peñuelas Saiz A, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open [Internet]. 2021 [cited 2022 Jan 15];6(3). Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128716/pdf/main.pdf 24.

  25. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov [Internet]. 2020 [cited 2022 Jan 15];10(6):783-791. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309152/pdf/candisc-10-783.pdf 25.

  26. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet [Internet]. 2020 [cited 2022 Jan 15];395(10241):1907-1918. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255743/pdf/main.pdf 26.

  27. Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. [Internet] 2020 [cited 2022 Jan 15];395(10241):1919-1926. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255715/pdf/main.pdf 27.

  28. Lara Álvarez MÁ, Rogado Revuelta J, Obispo Portero B, Pangua Méndez C, Serrano Montero G, López Alfonso A. Mortalidad por COVID-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Med Clin (Barc). [Internet]. 2020 [citado 15 Ene 2022];155(5):202-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236720/pdf/main.pdf 28.

  29. Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer [Internet]. 2020 [cited 2022 Jan 15];126(17):4023-4031. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361610/pdf/CNCR-9999-na.pdf 29.

  30. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan RS, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol [Internet]. 2020 [cited 2022 Jan 15];21(8):1023-1034. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417808/pdf/main.pdf 30.

  31. Korkusuz R, Sahingoz Erdal G, Kibar Akilli I, Bilge M, Tural D, Kart Yasar K. Changing characteristics of cancer patients during the COVID-19 pandemic. J Infect Dev Ctries [Internet]. 2022 [cited 2022 Apr 20];16(3):453-61. Available from: Available from: https://jidc.org/index.php/journal/article/view/35404850/2772 31.

  32. Guarneri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, et al. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. Eur J Cancer [Internet] 2021 [cited 2022 Jan 15];147:120-7. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857033/pdf/main.pdf 32.

  33. Mousavi SA, Rostami T, Kiumarsi A, Rad S, Rostami M, Motamedi F, et al. COVID-19 and cancer: A comparative case series. Cancer Treat Res Commun [Internet]. 2021 [cited 2022 Jan 15];27. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885684/pdf/main.pdf 33.

  34. Trifanescu OG, Gales L, Bacinschi X, Serbanescu L, Georgescu M, Sandu A, et al. Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania. In Vivo [Internet]. 2022 [cited 2022 Apr 20];36(2):934-941. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931923/pdf/in_vivo-36-934.pdf 34.

  35. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, Gino K, et al. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract [Internet]. 2021 [cited 2022 Jan 15];27(2):90-94. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831810/pdf/main.pdf 35.

  36. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J Cancer [Internet]. 2020 [cited 2022 Jan 15];132:199-206. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188643/pdf/main.pdf 36.

  37. Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Trans R Soc Trop Med Hyg [Internet]. 2022 [cited 2022 Apr 20];0:1-31. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992310/pdf/trac015.pdf 37.

  38. Busetto GM, Porreca A, Giudice FD, Maggi M, D'Agostino D, Romagnoli D, et al. SARS-CoV-2 infection and high-risk non-muscle-invasive bladder cancer: are there any common features. Urol Int [Internet]. 2020 [cited 2022 Jan 15];1-13. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316644/pdf/uin-0001.pdf 38.

  39. Garassino MC, Ribas A. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res [Internet]. 2021 [cited 2022 Jan 15];9(3):261-264. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052929/pdf/nihms-1691479.pdf 39.

  40. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer [Internet] 2021 [cited 2022 Jan 15];9(1). Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817383/pdf/jitc-2020-001931.pdf 40.




2020     |     www.medigraphic.com